

19th EAHP congress
26–28 March 2014, Barcelona

Satellite Symposium

Chemotherapy-induced neutropenia, treatment options and the patient perspective

Thursday
27 March
2014

11.45–13.15
Room 113

TEVA

Oncology

Scientific Symposium sponsored by Teva Pharmaceuticals B.V.

Teva Pharmaceuticals Europe BV, Piet Heinkade 107, 1019 GM Amsterdam, The Netherlands

Date of preparation: February 2014

CHAIR: ROB DUNCOMBE

Director of Pharmacy, Christie Hospital,
Manchester, UK

11.45 **Opening remarks**
Rob Duncombe, UK

11.50 **Chemotherapy-induced neutropenia (CIN) and the role of granulocyte colony stimulating factors (G-CSFs) in cancer treatment**
Bryan Hennessy, Ireland

12.20 **The great debate – long-acting vs short acting G-CSFs**

- The case for long-acting G-CSFs
Helen Flint, UK
- The case for short-acting G-CSFs
Olga Delgado, Spain
- Q&A for debate
- Vote and conclusions

12.55 **Implications for patients**
Karen Verrill, UK

13.15 **Closing remarks**
Rob Duncombe, UK